Install the Sina Finance client to receive the most comprehensive market information for the first time →[dolen lawrlwytho]
Clinical-stage biopharmaceutical company Alzamend Neuro ( ALZN.US ) said on Thursday it has submitted an experimental new drug application to the US Food and Drug Administration (FDA) seeking approval for its drug for the treatment of Alzheimer’s disease. Phase 1/2A trial of immunotherapy candidate ALZN002.
Alzamend Neuro says the product candidate contains dendritic cells, or activated white blood cells taken from one patient, so they can be engineered in vitro to block the beta amyloid protein associated with Alzheimer’s disease.
The Phase 1/2A trial was designed to evaluate the safety of multiple escalating doses of ALZN002 compared to placebo in 20 to 30 patients with mild to moderate Alzheimer’s disease, Alzamend Neuro said in a statement, tolerability and efficacy.
On Wednesday, Biogen (BIIB.US) announced that Lecanemab, a biologic drug for Alzheimer’s disease jointly developed with Japan’s Eisai, achieved positive results in a Phase 3 clinical trial. Affected by this news, stocks closed’ the US generally on Alzheimer’s disease stocks on Wednesday, and Alzamend Neuro closed up 6.31%.
Huge information, accurate interpretation, all in Sina Finance APP
Responsible editor: Guo Mingyu
